Biopharma | April 14, 2026
Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Nadda underlined that India’s policy framework is aligned with this transformation
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Subscribe To Our Newsletter & Stay Updated
